Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CortiFilm is a **nanotechnology-enabled topical transdermal film** being developed by **Velius** for **eczema**, especially **treatment-resistant eczema**. The product is designed to deliver **cortisone**, a corticosteroid, across the skin as a noninvasive alternative to injected corticosteroid therapy, and has been described as a \"cortisone shot without the needle.\" Its intended pharmacology is local activation of the **glucocorticoid receptor** in skin tissue to suppress inflammatory signaling and reduce eczema-related inflammation. Publicly available company materials indicate that CortiFilm is in development and awaiting FDA approval, but no formal clinical phase has been disclosed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CortiFilm.